D

Dong-A ST Co Ltd
KRX:170900

Watchlist Manager
Dong-A ST Co Ltd
KRX:170900
Watchlist
Price: 59 500 KRW -0.83%
Market Cap: 534.5B KRW
Have any thoughts about
Dong-A ST Co Ltd?
Write Note

P/E
Price to Earnings

-21.1
Current
36.4
Median
21.8
Industry
Lower than median
Lower than industry value

Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.

P/E
-21.1
=
Market Cap
511.6B KRW
/
Net Income
-24.2B KRW
All Countries
Close
Market Cap P/E
KR
Dong-A ST Co Ltd
KRX:170900
511.6B KRW -21.1
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY -5 347 888.9
US
Eli Lilly and Co
NYSE:LLY
755.8B USD 90.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP -15 783.5
DK
Novo Nordisk A/S
CSE:NOVO B
2.7T DKK 29
US
Johnson & Johnson
NYSE:JNJ
351.1B USD 23.9
US
Merck & Co Inc
NYSE:MRK
251.8B USD 20.7
CH
Roche Holding AG
SIX:ROG
200.1B CHF 17.4
UK
AstraZeneca PLC
LSE:AZN
161.8B GBP 31.5
CH
Novartis AG
SIX:NOVN
171.5B CHF 10.8
US
Pfizer Inc
NYSE:PFE
151.5B USD 35.6
Earnings Growth P/E to Growth
KR
D
Dong-A ST Co Ltd
KRX:170900
Average P/E: 32.4
Negative Multiple: -21.1
335%
N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
90.3
446%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
29
86%
0.3
US
Johnson & Johnson
NYSE:JNJ
23.9
-23%
N/A
US
Merck & Co Inc
NYSE:MRK
20.7
7 300%
0
CH
Roche Holding AG
SIX:ROG
17.4
54%
0.3
UK
AstraZeneca PLC
LSE:AZN
31.5
177%
0.2
CH
Novartis AG
SIX:NOVN
10.8
31%
0.3
US
Pfizer Inc
NYSE:PFE
35.6
719%
0

P/E Forward Multiples

Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/E
18.8
2-Years Forward
P/E
14.2
3-Years Forward
P/E
10.6

See Also

Discover More